{"product_id":"ghrs-vrio-analysis","title":"GH Research PLC (GHRS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the true competitive edge of GH Research PLC (GHRS) with this essential VRIO analysis. We distill whether its core resources are Valuable, Rare, Inimitable, and Organized to forge a sustainable advantage in the market. Dive in below to see the definitive verdict on what truly sets GH Research PLC (GHRS) apart from the competition.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGH Research PLC (GHRS) - VRIO Analysis: Proprietary Mebufotenin Drug Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core asset that defines GH Research PLC’s entire valuation story right now: their mebufotenin platform, specifically GH001 for treatment-resistant depression (TRD). Honestly, the near-term action hinges on how effectively they navigate the FDA response and launch their pivotal trials in 2026. Here’s the quick math on why this platform matters.\u003c\/p\u003e\n\n\u003ch\u003eValue: Foundation for Practice Change\u003c\/h\u003e\n\u003cp\u003eThe value here is massive because GH001, their proprietary inhalable mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) product candidate, offers a potential paradigm shift for TRD patients. The data from the Phase 2b trial (GH001-TRD-201) is compelling; it hit the primary endpoint with a -15.5 point placebo-adjusted reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score by Day 8. What this estimate hides is the clinical impact: 57.5% of treated patients achieved remission (MADRS≤10) versus 0% on placebo on Day 8. Plus, long-term data from the Open-Label Extension (OLE) shows a 73% remission rate at 6 months, all without mandated structured psychotherapy.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Uniqueness in the Current Landscape\u003c\/h\u003e\n\u003cp\u003eThe specific development and formulation - pulmonary inhalation of mebufotenin - is what makes this rare in the current market landscape for rapid-acting antidepressants. While the molecule itself is known, GH Research PLC’s execution around the delivery device and the specific clinical strategy for TRD is unique. They are preparing to initiate their global pivotal program in 2026, suggesting they are currently ahead of direct, similarly advanced competitors in this specific inhaled formulation space. They also have a second candidate, GH002 (intravenous mebufotenin HBr), which completed Phase 1 and is targeted for an Investigational New Drug (IND) submission in Q4 2025.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Protection Through IP and Process\u003c\/h\u003e\n\u003cp\u003eImitability is high for the core molecule, but the specific therapeutic application and the proprietary delivery system create significant barriers. GH Research PLC owns an intellectual property portfolio covering novel uses, manufacturing methods, novel salt forms, aerosol compositions, and device-related aspects of mebufotenin. The FDA clinical hold on the GH001 IND was a hurdle, but they believe the remaining issue regarding histology findings in rats is rat-specific, and they are actively working on the complete response submission. The complexity of replicating the successful clinical profile, which includes a single-day dosing paradigm and the proprietary aerosol device, makes direct imitation difficult, though not impossible over a long enough timeline.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Pipeline Alignment\u003c\/h\u003e\n\u003cp\u003eOrganizationally, GH Research PLC is definitely structured to exploit this platform. Their entire R\u0026amp;D focus, pipeline planning, and clinical strategy are built around this specific compound class. For the fiscal year ended December 31, 2024, R\u0026amp;D expenses were $35.0 million, showing a deep commitment to development, with Q3 2025 R\u0026amp;D expenses coming in at $10.6 million. The company’s cash position as of September 30, 2025, stood at $293.9 million, providing runway to support the planned 2026 pivotal program initiation. They have the necessary infrastructure to manage the regulatory path forward, even with the ongoing engagement with the FDA on the GH001 IND complete response.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage Scoring\u003c\/h\u003e\n\u003cp\u003eHere is how the platform stacks up based on the VRIO criteria. Remember, sustained advantage requires all four elements to be present.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eScore (1-4)\u003c\/td\u003e\n    \u003ctd\u003eImplication\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes, rapid, high remission rates in TRD.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003ePotential for competitive parity or advantage.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes, unique inhaled formulation\/delivery in this indication.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary competitive advantage.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eCostly\/Time-consuming due to IP and clinical data moat.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eTemporary competitive advantage.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eYes, entire strategy and cash position support the program.\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eOrganization is ready to exploit the resource.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe combination of high Value and strong Organization, coupled with the current Rarity and Imitability barriers, suggests a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e is achievable, provided they successfully resolve the IND hold and execute the pivotal trials. If onboarding takes 14+ days, churn risk rises, but the current data suggests a much faster treatment burden.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eGH001 Phase 2b Remission (Day 8): \u003cstrong\u003e57.5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e6-Month Remission (OLE): \u003cstrong\u003e73%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash Position (9\/30\/2025): \u003cstrong\u003e$293.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePivotal Program Start: Expected 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGH Research PLC (GHRS) - VRIO Analysis: GH001 Phase 2b Efficacy Data in TRD\n\u003c\/h2\u003e\n\u003cp\u003eGH001 Phase 2b Efficacy Data in TRD\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eProvides robust, statistically significant proof that GH001 works for Treatment-Resistant Depression (TRD), a massive unmet need.\u003c\/p\u003e\n\u003cp\u003eThe Phase 2b trial met its primary endpoint with a highly significant placebo adjusted reduction from baseline of \u003cstrong\u003e-15.5\u003c\/strong\u003e points in Montgomery-Åsberg Depression Rating Scale (MADRS) total score on Day 8 ($p\u0026lt;0.0001$).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eGH001 Result\u003c\/th\u003e\n\u003cth\u003ePlacebo Result\u003c\/th\u003e\n\u003cth\u003eStatistical Significance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlacebo-Adjusted MADRS Reduction (Day 8)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-15.5\u003c\/strong\u003e points\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e$p\u0026lt;0.0001$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemission Rate (Day 8)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e57.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$p\u0026lt;0.0001$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemission Rate (6 Months, OLE Completers)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eVery High. Achieving a -15.5 point placebo-adjusted reduction in MADRS score and a 57.5% remission rate on Day 8 is a standout result.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe trial recruited \u003cstrong\u003e81\u003c\/strong\u003e patients with TRD in the double-blind part (\u003cstrong\u003e40\u003c\/strong\u003e received GH001 and \u003cstrong\u003e41\u003c\/strong\u003e received placebo).\u003c\/li\u003e\n\u003cli\u003eOf the patients treated with GH001, \u003cstrong\u003e57.5%\u003c\/strong\u003e achieved remission (MADRS≤10) on Day 8 compared with \u003cstrong\u003e0%\u003c\/strong\u003e in the placebo group.\u003c\/li\u003e\n\u003cli\u003eOf the patients who achieved remission on Day 8 after their first active treatment, \u003cstrong\u003e90%\u003c\/strong\u003e were also in remission at month 6.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eHigh. Competitors can't easily replicate successful trial data that has already been generated.\u003c\/p\u003e\n\u003cp\u003eThe company reported \u003cstrong\u003e$315.3 million\u003c\/strong\u003e in cash and cash equivalents as of March 31, 2025.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh. Management is using this data to drive the pivotal program planning, set for 2026 initiation.\u003c\/p\u003e\n\u003cp\u003eGlobal pivotal program initiation is on track for \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe company had \u003cstrong\u003e$182.6 million\u003c\/strong\u003e in cash and equivalents as of December 31, 2024, plus additional net proceeds of \u003cstrong\u003e$139.8 million\u003c\/strong\u003e from a February 2025 public offering.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary. While strong now, this advantage will erode as pivotal trial data comes in and competitors advance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGH Research PLC (GHRS) - VRIO Analysis: Proprietary Inhalation Delivery Device\n\u003c\/h2\u003e\n\u003cp\u003e\nThe analysis below focuses exclusively on providing real-life statistical and financial figures relevant to the VRIO components of the Proprietary Inhalation Delivery Device for GH001.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThis device supports the pulmonary inhalation administration of GH001, central to the claims of convenience and rapid action.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nSpecialized delivery systems are rare in the pharmaceutical sector, though not entirely unique.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nWhile complex, engineering a similar device is feasible for a well-funded competitor over time. Intellectual property provides a barrier:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Metric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patent Families\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted European Patent Expiry (No Earlier Than)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2040\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe organization is actively engaged in validating the device for global use, supported by significant financial resources dedicated to R\u0026amp;D.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nPhase 1 clinical pharmacology trial (GH001-HV-106) to bridge data from the commercially available device is ongoing in the United Kingdom.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\/Operational Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, etc. (as of March 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$315.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, etc. (as of December 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$182.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Year Ended December 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$35.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Proceeds from Public Offering (February 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$139.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe advantage is currently viewed as temporary, contingent upon the lifespan of the device patent protection and the ability of rivals to develop workarounds.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGH Research PLC (GHRS) - VRIO Analysis: Broad Mebufotenin Intellectual Property Portfolio\n\u003c\/h2\u003e\n\u003cp\u003eThe Mebufotenin Intellectual Property Portfolio is assessed based on the following VRIO criteria:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe intellectual property protects the core science across multiple vectors, evidenced by the portfolio covering:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNovel uses for treatment via \u003cstrong\u003einhaled, nasal, buccal, sublingual, intravenous, intramuscular or subcutaneous routes\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNovel manufacturing methods for preparation and purification.\u003c\/li\u003e\n\u003cli\u003eHigh-purity forms and novel salt forms.\u003c\/li\u003e\n\u003cli\u003eNovel delivery device-related features, including a proprietary aerosol delivery device.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe value is further supported by clinical data demonstrating potential efficacy across indications:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTreatment-Resistant Depression (TRD) Phase 1\/2: Remission rates of \u003cstrong\u003e25% to 50%\u003c\/strong\u003e (single dose) or \u003cstrong\u003e87.5%\u003c\/strong\u003e (Individualized Dosing Regimen) at Day 8.\u003c\/li\u003e\n\u003cli\u003ePostpartum Depression (PPD) Phase 2a: \u003cstrong\u003eAll ten\u003c\/strong\u003e participants achieved remission by Day 8, with a \u003cstrong\u003e35.4 point\u003c\/strong\u003e reduction in MADRS score.\u003c\/li\u003e\n\u003cli\u003eBipolar II Disorder (BDII) Phase 2a: \u003cstrong\u003e33%\u003c\/strong\u003e remission rate and a \u003cstrong\u003e52%\u003c\/strong\u003e mean reduction in depressive symptoms by Day 8.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. While many biotechs possess intellectual property, the breadth covering the molecule, multiple administration uses, manufacturing, and device aspects is considered valuable.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. Patents serve as legally enforced barriers against direct copying of the claimed subject matter.\u003c\/p\u003e\n\u003cp\u003eThe portfolio includes the European Patent EP3927337, granted with an effective date of \u003cstrong\u003eFebruary 14, 2024\u003c\/strong\u003e, covering all Mebufotenin or salt products for MDD\/TRD use. This patent is expected to have an expiry date of no earlier than \u003cstrong\u003e2040\u003c\/strong\u003e. The company is advancing \u003cstrong\u003emore than 25\u003c\/strong\u003e unique international patent applications.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. The IP strategy directly supports the multi-indication pipeline development for TRD, BDII, and PPD. The company held \u003cstrong\u003e$182.6 million\u003c\/strong\u003e in cash and assets as of the end of 2024, providing organizational resources to manage and progress this portfolio.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. As long as the granted and pending patents remain legally enforced, this provides a long-term moat against direct competition for the claimed aspects of mebufotenin therapy.\u003c\/p\u003e\n\n\u003cp\u003eThe scope of the intellectual property portfolio is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Category\u003c\/th\u003e\n\u003cth\u003eSpecific Aspects Covered\u003c\/th\u003e\n\u003cth\u003eStatus\/Volume Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMebufotenin Product\u003c\/td\u003e\n\u003ctd\u003eMebufotenin (5-MeO-DMT) or pharmaceutically acceptable salt thereof\u003c\/td\u003e\n\u003ctd\u003eEuropean Patent Granted (EP3927337)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapeutic Use\u003c\/td\u003e\n\u003ctd\u003eTreatment of Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD)\u003c\/td\u003e\n\u003ctd\u003eExpiry no earlier than \u003cstrong\u003e2040\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoute of Administration\u003c\/td\u003e\n\u003ctd\u003eInhaled, nasal, buccal, sublingual, intravenous, intramuscular, subcutaneous\u003c\/td\u003e\n\u003ctd\u003eCovered in patent applications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\/Composition\u003c\/td\u003e\n\u003ctd\u003eNovel manufacturing methods, high-purity forms, novel salt forms, novel aerosol compositions of matter\u003c\/td\u003e\n\u003ctd\u003eIncluded in \u003cstrong\u003emore than 25\u003c\/strong\u003e international patent applications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery System\u003c\/td\u003e\n\u003ctd\u003eNovel delivery device-related features\u003c\/td\u003e\n\u003ctd\u003eIncluded in patent applications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eGH Research PLC (GHRS) - VRIO Analysis: Pipeline Breadth and Indication Diversity\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eReduces single-asset risk by having GH002 (IV formulation) and ongoing development in Bipolar II Disorder and Postpartum Depression (PPD) alongside the lead asset, GH001. The potential value is underscored by GH001 Phase 2b results in TRD, showing a 57.5% remission rate (MADRS $\\le$ 10) on Day 8 versus 0% for placebo (p\u0026lt;0.0001). Further value is suggested by the 73% remission rate at 6 months in the Open-Label Extension for GH001 in TRD.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003cth\u003eTarget Indication(s)\u003c\/th\u003e\n\u003cth\u003eDevelopment Status\/Key Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGH001\u003c\/td\u003e\n\u003ctd\u003eInhalation\u003c\/td\u003e\n\u003ctd\u003eTreatment-Resistant Depression (TRD)\u003c\/td\u003e\n\u003ctd\u003ePrimary endpoint met with -15.5 points MADRS reduction (Day 8)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGH001\u003c\/td\u003e\n\u003ctd\u003eInhalation\u003c\/td\u003e\n\u003ctd\u003eBipolar II Disorder\u003c\/td\u003e\n\u003ctd\u003ePhase 2 Open-Label Trial Completed (GH001-BD-202)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGH001\u003c\/td\u003e\n\u003ctd\u003eInhalation\u003c\/td\u003e\n\u003ctd\u003ePostpartum Depression (PPD)\u003c\/td\u003e\n\u003ctd\u003ePhase 2 Open-Label Trial Completed (GH001-PPD-203)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGH002\u003c\/td\u003e\n\u003ctd\u003eIntravenous (IV)\u003c\/td\u003e\n\u003ctd\u003ePipeline Asset\u003c\/td\u003e\n\u003ctd\u003ePhase 1 trial completed in 64 healthy volunteers (Q4 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Many clinical-stage firms focus on one indication; having multiple high-need areas (TRD, Bipolar II Disorder, PPD) for the mebufotenin platform is a plus.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eModerate. Competitors can pivot to other indications, but GH Research has a head start in these specific areas with completed Phase 2 open-label trials for GH001 in Bipolar II Disorder and PPD.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh. They are planning an IND submission for GH002 in Q4 2025, showing active pipeline management. The company reported $293.9 million in cash, cash equivalents and marketable securities as of September 30, 2025, supporting ongoing development activities.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eGH Research PLC reported net assets of $0.29 Billion USD as of September 2025.\u003c\/li\u003e\n\u003cli\u003eThe company is on track to commence its global pivotal program for GH001 in 2026.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expenses for the quarter ended September 30, 2025, were $10.6 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary. The lead asset's success, demonstrated by the 73% remission rate at 6 months for GH001 in TRD, dictates the value of the rest of the pipeline.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGH Research PLC (GHRS) - VRIO Analysis: Strong Balance Sheet and Cash Position\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue: Provides the necessary runway to fund the expensive transition from Phase 2 to the global pivotal program planned for 2026.\u003c\/h3\u003e\n\u003cp\u003eThe cash position as of June 30, 2025, was \u003cstrong\u003e$308.7 million\u003c\/strong\u003e in cash, cash equivalents and marketable securities, providing resources for the planned global pivotal program initiation in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Low. Many clinical-stage firms raise capital, but the specific amount is a tangible resource.\u003c\/h3\u003e\n\u003cp\u003eThe tangible resource is the specific quantum of capital available to fund operations until commercialization or the next financing event.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Low. Competitors can raise capital, but this is their current, specific war chest.\u003c\/h3\u003e\n\u003cp\u003eThe current balance sheet composition is unique to GHRS at this specific point in time.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: High. They successfully executed a $150.0 million public offering in Q1 2025 to bolster this position.\u003c\/h3\u003e\n\u003cp\u003eThe successful execution of the capital raise demonstrates organizational capability in securing necessary funding for development milestones.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross proceeds from the public offering in Q1 2025 were \u003cstrong\u003e$150.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe offering involved the sale of \u003cstrong\u003e10,000,000\u003c\/strong\u003e ordinary shares at a price of \u003cstrong\u003e$15.00\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eThe cash position increased from \u003cstrong\u003e$182.6 million\u003c\/strong\u003e as of December 31, 2024, to \u003cstrong\u003e$315.3 million\u003c\/strong\u003e as of March 31, 2025, following the offering.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe evolution of the cash position demonstrates the impact of the financing event:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDate\u003c\/th\u003e\n\u003cth\u003eCash, Cash Equivalents, and Marketable Securities (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$182.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarch 31, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$315.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$308.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$293.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company reported a net loss of \u003cstrong\u003e$9.3 million\u003c\/strong\u003e for the quarter ended June 30, 2025, and \u003cstrong\u003e$14.0 million\u003c\/strong\u003e for the quarter ended September 30, 2025.\u003c\/p\u003e\n\u003cp\u003eAs of September 30, 2025, Total Assets were \u003cstrong\u003e$302.02 million\u003c\/strong\u003e and Total Liabilities were \u003cstrong\u003e$10.62 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary. Cash is finite; this advantage lasts until the next major financing round or commercial launch.\u003c\/h3\u003e\n\u003cp\u003eThe advantage is contingent on the burn rate required to reach the \u003cstrong\u003e2026\u003c\/strong\u003e pivotal program initiation and subsequent milestones.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGH Research PLC (GHRS) - VRIO Analysis: Novel Treatment Paradigm: Convenience and Low Burden\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: The potential for a single-day administration with infrequent re-treatment and no mandated psychotherapy offers a huge advantage over current standards.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe anticipated therapeutic paradigm for mebufotenin-based therapies requires only a \u003cstrong\u003esingle day for initial administration\u003c\/strong\u003e. This convenience factor is supported by clinical observations where the majority of patients were ready for discharge within \u003cstrong\u003ean hour\u003c\/strong\u003e after the last dose, with \u003cstrong\u003eno post-discharge restrictions\u003c\/strong\u003e required. The treatment model explicitly excludes further structured psychotherapy or psychological support interventions, which are commonly required with other psychoactive compounds.\u003c\/p\u003e\n\u003cp\u003eThe efficacy data supports the low-burden model:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRemission at Day 8 in the Phase 2b trial was achieved in \u003cstrong\u003e57.5%\u003c\/strong\u003e of patients using GH001, compared to \u003cstrong\u003e0%\u003c\/strong\u003e in the placebo group.\u003c\/li\u003e\n\u003cli\u003eThe Open-Label Extension (OLE) analysis confirms a \u003cstrong\u003e73%\u003c\/strong\u003e remission rate at \u003cstrong\u003e6 months\u003c\/strong\u003e with \u003cstrong\u003einfrequent treatment visits\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePatients who achieved remission on Day 8 maintained a \u003cstrong\u003e91.7%\u003c\/strong\u003e remission rate at \u003cstrong\u003e6 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIn the OLE, a majority of patients received only \u003cstrong\u003e1-4 treatments\u003c\/strong\u003e over the six-month period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eThis convenience factor is a major differentiator against existing, time-consuming treatments. The ability to achieve ultra-rapid and durable remissions following a \u003cstrong\u003esingle dosing day\u003c\/strong\u003e positions GH001 uniquely in the treatment landscape for Treatment-Resistant Depression (TRD).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eGH001 (Anticipated Paradigm)\u003c\/td\u003e\n\u003ctd\u003eFinancial\/Operational Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Administration Timeframe\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSingle Dosing Day\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompany Cash Position as of September 30, 2025: \u003cstrong\u003e$293.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Dose Observation\/Discharge\u003c\/td\u003e\n\u003ctd\u003eReady for discharge within \u003cstrong\u003ean hour\u003c\/strong\u003e; \u003cstrong\u003eNo post-discharge restrictions\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMarket Capitalization: Approximately \u003cstrong\u003e$910.90 million\u003c\/strong\u003e to \u003cstrong\u003e$952.15 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRequired Psychotherapy\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNo mandated psychotherapeutic intervention\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShares Outstanding: \u003cstrong\u003e62.03M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e6-Month Remission Rate (OLE Completers)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast Twelve Months EBITDA: \u003cstrong\u003e-$48.41 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThis is a functional outcome of their molecule\/device combination, not just a feature. The ability to deliver mebufotenin via a proprietary pulmonary inhalation formulation (GH001) is central to this paradigm. The company owns an intellectual property portfolio relating to novel uses, manufacturing methods, and \u003cstrong\u003enovel device-related aspects\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThey highlight this benefit in investor communications, showing it’s central to their commercial story. The company's focus is on developing a \u003cstrong\u003epractice-changing treatment\u003c\/strong\u003e based on this novel approach. Analyst consensus reflects this potential, with price targets ranging from \u003cstrong\u003e$18 to $40 per share\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e. If proven in pivotal trials, this paradigm shift is hard for older drugs to match. The sustained remission rates of \u003cstrong\u003e73% at 6 months\u003c\/strong\u003e in the OLE suggest durability that challenges existing maintenance regimens.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eGH Research PLC (GHRS) - VRIO Analysis: Clinical Development and Data Interpretation Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Development and Data Interpretation Expertise\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The team successfully navigated a complex Phase 2b trial, generated long-term OLE data, and is managing the FDA IND hold response.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eGH001-TRD-201 Phase 2b Trial Data\u003c\/th\u003e\n\u003cth\u003eOLE Data (6 Months)\u003c\/th\u003e\n\u003cth\u003eIND Hold Status (as of July 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint (MADRS)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-15.5 points\u003c\/strong\u003e placebo-adjusted reduction from baseline on Day 8 (p\u0026lt;0.0001)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemission Rate (MADRS≤10)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e57.5%\u003c\/strong\u003e on Day 8 vs. \u003cstrong\u003e0%\u003c\/strong\u003e for placebo (p\u0026lt;0.0001)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e73%\u003c\/strong\u003e remission rate at 6 months\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety\/Tolerability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNo treatment-emergent events\u003c\/strong\u003e of suicidal ideation or behavior observed\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNo treatment related serious adverse events (SAEs)\u003c\/strong\u003e reported across the full 6-month duration\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Engagement\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eComplete response submitted to FDA in \u003cstrong\u003eJune 2025\u003c\/strong\u003e; \u003cstrong\u003eOnly one hold topic remaining\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Expertise in complex CNS trials is not universal, but it exists.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Key personnel are hard to poach, but scientific knowledge can be replicated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. They are actively engaging with Key Opinion Leaders (KOLs) to design the pivotal program.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEstablished a steering committee with \u003cstrong\u003eKOLs\u003c\/strong\u003e to review Phase 2b results and assist with pivotal program design.\u003c\/li\u003e\n\u003cli\u003eGlobal pivotal program initiation on track for \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCRO and site selection process is ongoing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Relies heavily on the current team's tenure and knowledge base.\u003c\/p\u003e\n\u003cp\u003eFinancial Context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities of \u003cstrong\u003e$315.3 million\u003c\/strong\u003e as of \u003cstrong\u003eMarch 31, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities of \u003cstrong\u003e$308.7 million\u003c\/strong\u003e as of \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization of \u003cstrong\u003e$1.04 billion\u003c\/strong\u003e as of \u003cstrong\u003eJuly 23, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eGH Research PLC (GHRS) - VRIO Analysis: Active and Focused Regulatory Engagement\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to actively engage the FDA and narrow down the clinical hold on the GH001 IND to a single, rat-specific issue demonstrates focused problem-solving.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe clinical hold on the Investigational New Drug Application (IND) for GH001 has been narrowed to one remaining issue to resolve as of July 2025.\u003c\/li\u003e\n\u003cli\u003eThe company submitted its complete response to the FDA in June 2025.\u003c\/li\u003e\n\u003cli\u003eThe remaining issue relates to 'respiratory tract histology findings in rats.'\u003c\/li\u003e\n\u003cli\u003eThe Phase 2b trial for GH001 in Treatment-Resistant Depression (TRD) met its primary endpoint with a placebo-adjusted Montgomery-Åsberg Depression Rating Scale (MADRS) reduction from baseline of \u003cstrong\u003e-15.5\u003c\/strong\u003e on Day 8 ($\\text{p}\u0026lt;0.0001$).\u003c\/li\u003e\n\u003cli\u003eRemission (MADRS$\\le 10$) was achieved by \u003cstrong\u003e57.5%\u003c\/strong\u003e of patients on Day 8, compared to \u003cstrong\u003e0%\u003c\/strong\u003e in the placebo group.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies struggle with holds; GH Research is clearly managing this specific hurdle.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. This is a specific, ongoing negotiation with a regulatory body.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. They are bolstering their response with expert opinion to resolve the final hold topic.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEngagement with the FDA on the complete response is ongoing, with the company actively working on a plan with 'respiratory, toxicology and regulatory experts.'\u003c\/li\u003e\n\u003cli\u003eThe company reported a Current Ratio of \u003cstrong\u003e17.2261\u003c\/strong\u003e as of Q3 2025.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities were \u003cstrong\u003e\\$293.9 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The advantage exists only until the hold is fully resolved or a new regulatory hurdle appears.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Financial\/Statistical Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDemonstrated by focused resolution of regulatory hold\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e73%\u003c\/strong\u003e remission rate at 6 months for GH001 in OLE data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eNet Loss for Q3 2025 was \u003cstrong\u003e\\$14.0 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses for Q3 2025 were \u003cstrong\u003e\\$10.6 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eG\u0026amp;A Expenses for Q3 2025 were \u003cstrong\u003e\\$6.0 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, other financial assets and marketable securities as of December 31, 2024: \u003cstrong\u003e\\$182.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet cash proceeds from public offering received in February 2025: \u003cstrong\u003e\\$139.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGross proceeds from public offering in Q1 2025: \u003cstrong\u003e\\$150.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516172230805,"sku":"ghrs-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ghrs-vrio-analysis.png?v=1740177657","url":"https:\/\/dcf-model.com\/pt\/products\/ghrs-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}